Eric Dobmeier
Eric Dobmeier's purchase track record
Eric Dobmeier has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2023 | ATRA | $101K | +256.5% | +130.4% | +18.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Transaction History
| JANX | ▲ Buy | Grant | 5,500 | $0 | 6/11/2026 | View on chart |
| JANX | ▲ Buy | Grant | 3,750 | $0 | 6/11/2025 | View on chart |
| JANX | ▲ Buy | Grant | 5,000 | $0 | 7/19/2024 | View on chart |
| JANX | ▲ Buy | Grant | 2,500 | $0 | 7/19/2024 | View on chart |
| ATRA | ▲ Buy | Open Market | 446,825 | $101K | 11/10/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program
The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program. The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.